Mehmet Zafer Sabuncuoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mehmet Zafer Sabuncuoğlu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- İsmail Zihni
Department of General Surgery, Akdeniz University Faculty of Medicine, Antalya 07070, Türkiye
10 shared publications - Isa Karaca
Süleyman Demirel University
8 shared publications - Bilal Turan
Süleyman Demirel Üniversitesi
7 shared publications - Girayhan Çelik
SÜLEYMAN DEMİREL ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALI
6 shared publications Isa Sozen
Hepatopancreatobiliary and Liver Transplantation Unit, Department of General Surgery, Suleyman Demirel University, Faculty of Medicine, Isparta, Turkey
6 shared publications- Serdar Acar
Department of General Surgery, Faculty of Medicine, Süleyman Demirel University, Isparta, Türkiye
6 shared publications
Latest Publications
- Open Access
Competing Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity
Background and Objectives: Adenoid cystic carcinoma of the breast is a rare special-type tumor that is characteristically triple-negative yet behaves indolently, unlike conventional triple-negative disease. How its mortality is divided between the cancer itself and competing causes, and how that balance changes with age, has not been characterized in a contemporary population-based cohort. Materials and Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER-17, 2000–2023), we identified women with primary breast adenoid cystic carcinoma (ICD-O-3 8200/3). After restriction to first or only malignant primaries and exclusion of metastatic disease, 917 patients were analyzed. Breast cancer-specific survival (BCSS) and overall survival were estimated by Kaplan–Meier; competing-risk cumulative incidence (breast cancer vs. other-cause death) was estimated by the Aalen–Johansen estimator, overall and by age, with differences across age groups tested. Determinants of breast cancer death were modeled with cause-specific Cox regression restricted to patients with known grade. Results: The median age was 62 years; of the whole cohort, 81.4% of tumors were localized and 3.5% were node-positive, and 75.6% of classifiable cases were triple-negative. BCSS was 95.9%, 93.3%, and 91.2% at 5, 10, and 15 years. Although 205 women (22.4%) died, only 53 (5.8%) died of breast cancer; the 15-year cumulative incidence of non-cancer death (24.0%) was threefold that of breast cancer death (8.1%) and approximated the expected background mortality for this age. Breast cancer death did not differ across age groups, whereas other-cause death rose steeply with age: at 10 years, it reached 39% versus 7% for cancer in women aged ≥ 70, in whom only 13% of all deaths were cancer-related. Among patients with known grade, node positivity (hazard ratio 8.40) and high grade (2.42) predicted breast cancer death, whereas age did not. The competing-mortality structure was unchanged in the documented triple-negative subset. Conclusions: Breast adenoid cystic carcinoma is a predominantly triple-negative but indolent malignancy in which competing, non-cancer mortality dominates the clinical course, overwhelmingly so in older women, and breast cancer death is largely confined to high-grade, node-positive tumors. These findings favor individualized, age-adapted management rather than routine escalation based on the triple-negative label alone.
Open AccessCompeting Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity
Background and Objectives: Adenoid cystic carcinoma of the breast is a rare special-type tumor that is characteristically triple-negative yet behaves indolently, unlike conventional triple-negative disease. How its mortality is divided between the cancer itself and competing causes, and how that balance changes with age, has not been characterized in a contemporary population-based cohort. Materials and Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER-17, 2000–2023), we identified women with primary breast adenoid cystic carcinoma (ICD-O-3 8200/3). After restriction to first or only malignant primaries and exclusion of metastatic disease, 917 patients were analyzed. Breast cancer-specific survival (BCSS) and overall survival were estimated by Kaplan–Meier; competing-risk cumulative incidence (breast cancer vs. other-cause death) was estimated by the Aalen–Johansen estimator, overall and by age, with differences across age groups tested. Determinants of breast cancer death were modeled with cause-specific Cox regression restricted to patients with known grade. Results: The median age was 62 years; of the whole cohort, 81.4% of tumors were localized and 3.5% were node-positive, and 75.6% of classifiable cases were triple-negative. BCSS was 95.9%, 93.3%, and 91.2% at 5, 10, and 15 years. Although 205 women (22.4%) died, only 53 (5.8%) died of breast cancer; the 15-year cumulative incidence of non-cancer death (24.0%) was threefold that of breast cancer death (8.1%) and approximated the expected background mortality for this age. Breast cancer death did not differ across age groups, whereas other-cause death rose steeply with age: at 10 years, it reached 39% versus 7% for cancer in women aged ≥ 70, in whom only 13% of all deaths were cancer-related. Among patients with known grade, node positivity (hazard ratio 8.40) and high grade (2.42) predicted breast cancer death, whereas age did not. The competing-mortality structure was unchanged in the documented triple-negative subset. Conclusions: Breast adenoid cystic carcinoma is a predominantly triple-negative but indolent malignancy in which competing, non-cancer mortality dominates the clinical course, overwhelmingly so in older women, and breast cancer death is largely confined to high-grade, node-positive tumors. These findings favor individualized, age-adapted management rather than routine escalation based on the triple-negative label alone.
- Open Access
- 22 October 2026
- Published by Springer Nature in Discover Oncology
Histological purity is independently associated with breast cancer-specific survival in mucinous breast carcinoma: a population-based analysis
- 22 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessHistological purity is independently associated with breast cancer-specific survival in mucinous breast carcinoma: a population-based analysis
- Open Access
Competing Mortality, Not Breast-Cancer Mortality, Explains the Survival Deficit of Breast Cancer After a Prior Non-Breast Cancer: A SEER Competing-Risks Analysis
Background and Objectives: Women who develop breast cancer after a previous cancer of another site have poorer overall survival, yet it is unsettled whether the breast cancer itself is more lethal or whether the deficit reflects competing causes of death in an older, previously treated population. We decomposed this survival deficit by cause of death, defining every endpoint identically across groups. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (17 registries, 2010 to 2020), we studied women with invasive breast cancer as a single primary (n = 473,073), as a second or later primary after a non-breast index cancer (second primary breast cancer, SPBC; n = 26,832), and as a second breast primary (n = 40,252). Cause of death was assigned from the SEER cause-of-death-to-site recode, applied identically across cohorts. Cohorts were compared using cause-specific and Fine–Gray models weighted by an inverse-probability propensity score for age, race and ethnicity, subtype, grade, stage, nodal status, year, marital status, income, and rurality. Results: Breast-cancer mortality was not higher in SPBC than in single-primary disease, and was if anything lower (10-year cumulative incidence 12.0 versus 13.6 percent; weighted cause-specific hazard ratio 1.06). The deficit fell almost entirely to competing, non-breast mortality (35.3 versus 13.5 percent). In a five-way decomposition, cardiovascular disease was not the leading competing cause; non-cancer causes and the index cancer each accounted for more deaths. Once patient factors were balanced, cardiovascular and other non-cancer hazards were near unity (1.05 and 1.07), leaving further cancer death as the main excess. Conclusions: A breast cancer arising after a non-breast cancer is not intrinsically more lethal. Its survival deficit is competing mortality, driven mainly by further cancer death and, to a smaller and largely age-explained degree, by cardiovascular and other non-cancer causes.
Open AccessCompeting Mortality, Not Breast-Cancer Mortality, Explains the Survival Deficit of Breast Cancer After a Prior Non-Breast Cancer: A SEER Competing-Risks Analysis
Background and Objectives: Women who develop breast cancer after a previous cancer of another site have poorer overall survival, yet it is unsettled whether the breast cancer itself is more lethal or whether the deficit reflects competing causes of death in an older, previously treated population. We decomposed this survival deficit by cause of death, defining every endpoint identically across groups. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (17 registries, 2010 to 2020), we studied women with invasive breast cancer as a single primary (n = 473,073), as a second or later primary after a non-breast index cancer (second primary breast cancer, SPBC; n = 26,832), and as a second breast primary (n = 40,252). Cause of death was assigned from the SEER cause-of-death-to-site recode, applied identically across cohorts. Cohorts were compared using cause-specific and Fine–Gray models weighted by an inverse-probability propensity score for age, race and ethnicity, subtype, grade, stage, nodal status, year, marital status, income, and rurality. Results: Breast-cancer mortality was not higher in SPBC than in single-primary disease, and was if anything lower (10-year cumulative incidence 12.0 versus 13.6 percent; weighted cause-specific hazard ratio 1.06). The deficit fell almost entirely to competing, non-breast mortality (35.3 versus 13.5 percent). In a five-way decomposition, cardiovascular disease was not the leading competing cause; non-cancer causes and the index cancer each accounted for more deaths. Once patient factors were balanced, cardiovascular and other non-cancer hazards were near unity (1.05 and 1.07), leaving further cancer death as the main excess. Conclusions: A breast cancer arising after a non-breast cancer is not intrinsically more lethal. Its survival deficit is competing mortality, driven mainly by further cancer death and, to a smaller and largely age-explained degree, by cardiovascular and other non-cancer causes.
- 10 October 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 343
Stage and age as distinct determinants of competing mortality in parathyroid carcinoma: a population-based analysis
- 10 October 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 343
Stage and age as distinct determinants of competing mortality in parathyroid carcinoma: a population-based analysis
- 6 October 2026
- Published by Wiley in International Journal of Cancer
Stability of GLOBOCAN Estimates Across Consecutive Releases: A Quantitative Benchmark for Global Cancer Epidemiology
GLOBOCAN is the most widely used source of national cancer statistics, yet users routinely treat the difference between two releases as real epidemiological change. We quantified how far estimates move between the 2022 and 2024 cycles and whether this depends on development level. Age‐standardised incidence and mortality rates for eight cancers were paired between GLOBOCAN 2022 and 2024 for 185 countries common to both cycles. Agreement was assessed by Bland–Altman analysis and Lin's concordance correlation coefficient (CCC); per‐country revision magnitude was related to the Human Development Index (HDI) using rank and robust regression, with partial correlation adjusting for baseline incidence. Pooled concordance was high (CCC 0.97 for incidence, 0.95 for mortality) with negligible mean bias, but limits of agreement were wide and the tail heavy: 62.4%, 40.3%, 28.1% and 13.4% of country–cancer–sex cells were revised by more than 10%, 20%, 30% and 50%. Revision magnitude was inversely related to HDI (Spearman ρ = −0.62 for incidence and −0.62 for mortality; both p < 0.001), falling from 23.3% in low‐HDI to 8.1% in very‐high‐HDI countries and persisted after adjustment for baseline incidence (partial ρ = −0.36); the development gradient is thus only partly explained by lower, more volatile baseline rates. Thyroid cancer showed the largest revisions. These findings provide, to our knowledge, the first quantitative benchmark for interpreting apparent differences between successive GLOBOCAN releases and support more cautious interpretation of single‐cycle estimates from lower‐HDI settings.
- 6 October 2026
- Published by Wiley in International Journal of Cancer
Stability of GLOBOCAN Estimates Across Consecutive Releases: A Quantitative Benchmark for Global Cancer Epidemiology
GLOBOCAN is the most widely used source of national cancer statistics, yet users routinely treat the difference between two releases as real epidemiological change. We quantified how far estimates move between the 2022 and 2024 cycles and whether this depends on development level. Age‐standardised incidence and mortality rates for eight cancers were paired between GLOBOCAN 2022 and 2024 for 185 countries common to both cycles. Agreement was assessed by Bland–Altman analysis and Lin's concordance correlation coefficient (CCC); per‐country revision magnitude was related to the Human Development Index (HDI) using rank and robust regression, with partial correlation adjusting for baseline incidence. Pooled concordance was high (CCC 0.97 for incidence, 0.95 for mortality) with negligible mean bias, but limits of agreement were wide and the tail heavy: 62.4%, 40.3%, 28.1% and 13.4% of country–cancer–sex cells were revised by more than 10%, 20%, 30% and 50%. Revision magnitude was inversely related to HDI (Spearman ρ = −0.62 for incidence and −0.62 for mortality; both p < 0.001), falling from 23.3% in low‐HDI to 8.1% in very‐high‐HDI countries and persisted after adjustment for baseline incidence (partial ρ = −0.36); the development gradient is thus only partly explained by lower, more volatile baseline rates. Thyroid cancer showed the largest revisions. These findings provide, to our knowledge, the first quantitative benchmark for interpreting apparent differences between successive GLOBOCAN releases and support more cautious interpretation of single‐cycle estimates from lower‐HDI settings.
- 8 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 1-8
Incidence and Treatment Patterns of Pleomorphic Lobular Carcinoma in Situ: A Population-based Analysis After the Introduction of ICD-O-3 Code 8519/2
- 8 September 2026
- Published by Elsevier in Clinical Breast Cancer
- Vol. 26 (11) , 1-8
Incidence and Treatment Patterns of Pleomorphic Lobular Carcinoma in Situ: A Population-based Analysis After the Introduction of ICD-O-3 Code 8519/2
- Open Access
- 18 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Circulatory and other-cause mortality after neoadjuvant versus adjuvant chemotherapy in women with stage II–III breast cancer
Most women with operable breast cancer increasingly survive long enough for non-cancer causes to become important contributors to mortality, particularly at older ages. We investigated whether the recorded sequence of systemic therapy relative to surgery among women receiving chemotherapy was associated with circulatory mortality and examined how causes of death evolve in long-term survivors. This retrospective population-based cohort study included 74,233 women with stage II–III non-metastatic invasive breast cancer diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) database who received chemotherapy and definitive surgery. A six-month landmark was used to reduce immortal-time bias, and treatment groups were balanced using stabilized inverse-probability-of-treatment weighting. Weighted cumulative incidence, cause-specific hazard, and Fine–Gray subdistribution models were used to evaluate circulatory mortality, while mortality patterns after a five-year landmark were examined descriptively by age. Median follow-up was 10.8 years. The weighted 10-year cumulative incidence of circulatory death was 2.06% after recorded preoperative systemic therapy and 2.10% after postoperative therapy, corresponding to a risk difference of −0.05 percentage points (95% confidence interval [CI], −0.31 to 0.18). The cause-specific hazard ratio was 1.092 (95% CI, 0.968–1.231), and the subdistribution hazard ratio was 1.024 (95% CI, 0.920–1.140). Among deaths occurring after the five-year landmark, the circulatory share increased with age, reaching 25.5% in women aged ≥75 years at diagnosis; however, other non-circulatory causes remained the largest category (49.9%). In women aged ≥75 years who survived five years, circulatory mortality approached and eventually exceeded breast-cancer mortality, but the difference was not significant at the prespecified seven-year time point. The recorded systemic-therapy/surgery sequence was not associated with long-term circulatory mortality. In older long-term breast-cancer survivors, late mortality is predominantly multimorbid rather than circulatory-dominant, supporting survivorship care that addresses cardiovascular risk within a broader framework of age-related competing health risks.
- 18 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Open AccessCirculatory and other-cause mortality after neoadjuvant versus adjuvant chemotherapy in women with stage II–III breast cancer
Most women with operable breast cancer increasingly survive long enough for non-cancer causes to become important contributors to mortality, particularly at older ages. We investigated whether the recorded sequence of systemic therapy relative to surgery among women receiving chemotherapy was associated with circulatory mortality and examined how causes of death evolve in long-term survivors. This retrospective population-based cohort study included 74,233 women with stage II–III non-metastatic invasive breast cancer diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results (SEER) database who received chemotherapy and definitive surgery. A six-month landmark was used to reduce immortal-time bias, and treatment groups were balanced using stabilized inverse-probability-of-treatment weighting. Weighted cumulative incidence, cause-specific hazard, and Fine–Gray subdistribution models were used to evaluate circulatory mortality, while mortality patterns after a five-year landmark were examined descriptively by age. Median follow-up was 10.8 years. The weighted 10-year cumulative incidence of circulatory death was 2.06% after recorded preoperative systemic therapy and 2.10% after postoperative therapy, corresponding to a risk difference of −0.05 percentage points (95% confidence interval [CI], −0.31 to 0.18). The cause-specific hazard ratio was 1.092 (95% CI, 0.968–1.231), and the subdistribution hazard ratio was 1.024 (95% CI, 0.920–1.140). Among deaths occurring after the five-year landmark, the circulatory share increased with age, reaching 25.5% in women aged ≥75 years at diagnosis; however, other non-circulatory causes remained the largest category (49.9%). In women aged ≥75 years who survived five years, circulatory mortality approached and eventually exceeded breast-cancer mortality, but the difference was not significant at the prespecified seven-year time point. The recorded systemic-therapy/surgery sequence was not associated with long-term circulatory mortality. In older long-term breast-cancer survivors, late mortality is predominantly multimorbid rather than circulatory-dominant, supporting survivorship care that addresses cardiovascular risk within a broader framework of age-related competing health risks.
- Open Access
- 4 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Competing cardiovascular and tumor-specific mortality in malignant phyllodes tumor
Malignant phyllodes tumor of the breast is a rare neoplasm, and its long-term competing causes of death remain insufficiently characterized. This study aimed to quantify phyllodes-specific and cardiovascular mortality and determine whether cardiovascular mortality exceeds that expected in the general female population. Women with histologically confirmed malignant phyllodes tumor diagnosed between 2000 and 2020 were identified in the Surveillance, Epidemiology, and End Results (SEER) 17-registry database. Phyllodes-specific, cardiovascular, and other-cause mortality were evaluated using competing-risk methods, while cardiovascular standardized mortality ratios (SMRs) were calculated using United States female circulatory-disease rates and person-time distributed across attained-age strata by Lexis expansion. Among 2106 women followed for a median of 165 months, 294 died from phyllodes-specific causes, 83 from cardiovascular causes, and 163 from other causes. Phyllodes-specific mortality remained the dominant competing risk throughout follow-up, with 180-month cumulative incidences of 14.6% for phyllodes-specific death and 4.4% for cardiovascular death. Cardiovascular mortality was not elevated relative to the general female population when person-time was standardized by attained age (SMR 0.92; 95% confidence interval 0.74–1.14) or additionally by calendar period (SMR 1.00; 95% confidence interval 0.80–1.24). In contrast, assigning all person-time to age at diagnosis produced an inflated SMR of 1.95. Phyllodes-specific death therefore remains the principal long-term mortality risk in malignant phyllodes tumor, whereas the apparent excess cardiovascular mortality results from incorrect person-time allocation rather than a true increase in risk.
- 4 August 2026
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
Open AccessCompeting cardiovascular and tumor-specific mortality in malignant phyllodes tumor
Malignant phyllodes tumor of the breast is a rare neoplasm, and its long-term competing causes of death remain insufficiently characterized. This study aimed to quantify phyllodes-specific and cardiovascular mortality and determine whether cardiovascular mortality exceeds that expected in the general female population. Women with histologically confirmed malignant phyllodes tumor diagnosed between 2000 and 2020 were identified in the Surveillance, Epidemiology, and End Results (SEER) 17-registry database. Phyllodes-specific, cardiovascular, and other-cause mortality were evaluated using competing-risk methods, while cardiovascular standardized mortality ratios (SMRs) were calculated using United States female circulatory-disease rates and person-time distributed across attained-age strata by Lexis expansion. Among 2106 women followed for a median of 165 months, 294 died from phyllodes-specific causes, 83 from cardiovascular causes, and 163 from other causes. Phyllodes-specific mortality remained the dominant competing risk throughout follow-up, with 180-month cumulative incidences of 14.6% for phyllodes-specific death and 4.4% for cardiovascular death. Cardiovascular mortality was not elevated relative to the general female population when person-time was standardized by attained age (SMR 0.92; 95% confidence interval 0.74–1.14) or additionally by calendar period (SMR 1.00; 95% confidence interval 0.80–1.24). In contrast, assigning all person-time to age at diagnosis produced an inflated SMR of 1.95. Phyllodes-specific death therefore remains the principal long-term mortality risk in malignant phyllodes tumor, whereas the apparent excess cardiovascular mortality results from incorrect person-time allocation rather than a true increase in risk.
- 31 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104, 103181
Beyond development: Global disparities in gastrointestinal cancer outcomes across 176 countries
- 31 July 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 104, 103181
Beyond development: Global disparities in gastrointestinal cancer outcomes across 176 countries